Merck
CN
所有图片(1)

文件

安全信息

R8404

Sigma-Aldrich

Rufinamide

≥98% (HPLC), powder

登录查看公司和协议定价
所有图片(1)
别名:
1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide
经验公式（希尔记法）:
C10H8F2N4O
CAS号:
106308-44-5
分子量:
238.19
MDL编号:
MFCD00865314
PubChem化学物质编号:
24724595
NACRES:
NA.77

质量水平

100

检测方案

≥98% (HPLC)

形式

powder

颜色

white

溶解性

DMSO: 9 mg/mL

创始人

Novartis

储存温度

−20°C

SMILES字符串

NC(=O)c1cn(Cc2c(F)cccc2F)nn1

InChI

1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)

InChI key

POGQSBRIGCQNEG-UHFFFAOYSA-N

基因信息

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

正在寻找类似产品? Visit 产品对比指南

应用

Rufinamide has been used to test its analgesic effect on neuropathic pain in spared nerve injury (SNI) model.

生化/生理作用

Rufinamide may elicit inhibition of the sodium channels and block action potential generation. This property makes it an antiepileptic drug for treating epilepsy disorders like Lennox-Gastaut syndrome.
Broad-spectrum anticonvulsant.

特点和优势

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

诊断含义

Effective therapy for partial seizures in adults and childhood seizures in Lennox-Gastaut syndrome.

象形图

Exclamation markHealth hazard
GHS07,GHS08

警示用语：

Warning

危险分类

Carc. 2 - Repr. 2 - STOT SE 3

靶器官

Central nervous system

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

为方便起见，与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码？

在网站页面上，产品编号会附带包装尺寸/数量一起显示（例如：T1503-25G）。请确保 在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503
货号
-
25G
包装规格/数量

其它示例：

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题？欢迎随时联系我们技术服务 寻求帮助

批号可以在产品标签上"批“ （Lot或Batch）字后面找到。

Aldrich 产品

  • 如果您查询到的批号为 TO09019TO 等，请输入去除前两位字母的批号：09019TO。

  • 如果您查询到的批号含有填充代码（例如05427ES-021），请输入去除填充代码-021的批号：05427ES。

  • 如果您查询到的批号含有填充代码（例如 STBB0728K9），请输入去除填充代码K9的批号：STBB0728。

未找到您寻找的产品？

部分情况下，可能未在线提供COA。如果搜索不到COA，可在线索取。

索取COA

Alberto Verrotti et al.
Pediatric neurology, 44(5), 347-349 (2011-04-13)
Rufinamide is a new orally active antiepileptic drug that has been found to be effective in the treatment of partial seizures and drop attacks associated with Lennox-Gastaut syndrome. We performed a quantitative analysis of the efficacy of this new antiepileptic
Maria G Dahlin et al.
Neuropediatrics, 43(5), 264-270 (2012-09-04)
We examined the influence of age and type of concomitant antiepileptic drugs (AEDs) on the pharmacokinetics of rufinamide (RUF) as well as its efficacy and safety in 51 children with refractory epilepsy. In a retrospective noninterventional survey, dose-to-concentration ratios of
C von Stülpnagel et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 16(5), 459-463 (2012-01-24)
We evaluated the long-term efficacy and tolerability of the orphan drug rufinamide (RUF) in children with pharmacoresistant myoclonic-astatic epilepsy (MAE, Doose syndrome). This was a retrospective European multicenter study on eight patients who had started an intention-to-treat trial of RUF
Christopher S Wisniewski
The Annals of pharmacotherapy, 44(4), 658-667 (2010-03-18)
To review the pharmacology, pharmacokinetics, efficacy, and safety of rufinamide in the treatment of epileptic seizures and describe its potential place in therapy. MEDLINE (1966-January 2010) and PubMed (1966-January 2010) literature searches were conducted to identify primary literature investigating rufinamide.
Isabelle Mourand et al.
Epilepsia, 54(1), e5-e8 (2012-07-12)
Rufinamide (RUF) is a novel antiepileptic drug considered as second-line therapy in the treatment of Lennox-Gastaut syndrome. Treatment-emergent adverse events (AEs) have consisted mainly of drowsiness, irritability, vomiting, and loss of appetite. RUF is considered as a "weight-neutral" drug. We
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门